Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$25.57 USD
-0.01 (-0.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $25.50 -0.07 (-0.27%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANIK 25.57 -0.01(-0.04%)
Will ANIK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ANIK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIK
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
ANIK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Other News for ANIK
Medicare Administrators looking to 'drastically shake up' wound care, says BTIG
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Anika Therapeutics: Strong Q4 Performance and Upbeat FY2024 Outlook Justify Buy Rating and Raised Price Target
Anika Therapeutics price target raised by $8 at Barrington, here's why